



Viral Markers of Hepatitis B and C: A Comprehensive Assessment

Mr Pankaj Kumar¹, Prof.Dr.Madhurendra Singh²

¹Research Scholar, Malwanchal University, Indore.

²Research Supervisor, Malwanchal University, Indore.

Introduction

Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are significant global health concerns, affecting millions of people worldwide. These viruses primarily target the liver and can lead to chronic liver disease, cirrhosis, and hepatocellular carcinoma if left untreated. Early detection and accurate diagnosis are crucial for timely intervention and improved patient outcomes.

One of the essential aspects of diagnosing hepatitis B and C is the identification and understanding of viral markers. These markers, including antigens and antibodies, play a pivotal role in screening, diagnosing acute and chronic infections, monitoring disease progression, and assessing response to treatment. In this article, we will explore the viral markers associated with Hepatitis B and C infections, their significance in diagnosis and management, and the available diagnostic tests.

Hepatitis B Virus Markers

Hepatitis B surface antigen (HBsAg): HBsAg is the hallmark marker for acute and chronic HBV infection. It is the earliest detectable antigen in the serum and indicates active viral replication. Its presence for more than six months typically indicates chronic HBV infection. The detection of HBsAg is the cornerstone for screening blood products, assessing vaccine response, and diagnosing acute and chronic infections.

Hepatitis B e antigen (HBeAg): HBeAg is an indicator of active viral replication and high infectivity. Its presence is associated with a higher risk of chronicity. Monitoring HBeAg status helps assess disease progression and guide treatment decisions.

Hepatitis B core antigen (HBcAg): HBcAg is a viral nucleocapsid antigen that is not detected in the blood but can be detected in liver tissue during a biopsy. HBcAg is important in determining the replicative status of the virus and is used to differentiate between acute and chronic infections.

Hepatitis B antibodies: Antibodies against HBV are crucial for diagnosing and monitoring infection. Anti-HBs antibodies develop after recovery from acute HBV infection or following successful vaccination. Anti-HBc antibodies are markers of previous or ongoing infection, while the presence of both anti-HBs and anti-HBc indicates resolved infection.

Hepatitis C Virus Markers

Hepatitis C antibodies (anti-HCV): Anti-HCV antibodies are the primary markers used to screen for HCV infection. They appear several weeks after exposure to the virus and persist throughout the infection. A positive anti-HCV test indicates exposure to HCV but does not differentiate between acute and chronic infection.

HCV RNA: HCV RNA is a direct marker of active viral replication. It is detected in the blood using nucleic acid amplification tests (NAATs). The presence of HCV RNA confirms an ongoing infection, and its quantification helps monitor treatment response and guide therapy duration.

HCV genotyping: HCV exhibits significant genetic diversity, with at least six major genotypes and multiple subtypes. Genotyping is essential in guiding treatment decisions, as different genotypes may respond differently to antiviral therapies.

Liver function tests: While not specific to HCV infection, liver function tests are routinely performed to assess liver health and identify possible liver damage. Elevated liver enzymes, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), indicate liver inflammation.

Diagnostic Tests and Management

The diagnosis of hepatitis B and C infections involves a combination of serological tests, molecular assays, and liver function tests. Common diagnostic tests include enzyme immunoassays (EIAs), polymerase chain reaction (PCR), and liver biopsy.

Management of HBV and HCV infections focuses on antiviral therapy, regular monitoring of viral markers, and liver function assessment. Antiviral treatment options have evolved significantly over the years, with newer drugs offering improved efficacy and tolerability.

Conclusion

Viral markers play a critical role in the diagnosis, monitoring, and management of hepatitis B and C infections. The presence or absence of specific markers helps determine the stage of infection, guide treatment decisions, and assess treatment response. Regular monitoring of viral markers is essential to ensure appropriate medical interventions and prevent the progression of liver disease. Advances in diagnostic tests and antiviral therapies continue to enhance our ability to combat these challenging viral infections and improve patient outcomes.

Reference

- 1) World Health Organization. Hepatitis B. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b>. Accessed 20 May 2019.
- 2) World Health Organization. Hepatitis C. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>. Accessed 20 May 2019.
- 3) Ministry of Health—Secretariat of Health Surveillance—Department of Surveillance, Prevention and Control of STIs, HIV/AIDS and Hepatitis Viral (DIAHV). Epidemiological bulletin—viral hepatitis. <https://www.aids.gov.br/pt-br/pub/2018/boletim-epidemiologico-de-hepatites-virais-2018>. Accessed 20 May 2019.
- 4) Villar LM, Cruz HM, Barbosa JR, Bezerra CS, Portilho MM, Scalioni LP. Update on hepatitis B and C virus diagnosis. *World J Virol*. 2015;4(4):323–42.
- 5) World Health Organization. Global health sector strategy on viral hepatitis 2016–2021; 2016. <https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/>. Accessed 20 May 2019.
- 6) Cruz HM, Miguel Cruz JC, Da Silva EF, Portilho MM, Marques VA, Lewis-Ximenez LL, Lampe E, Villar LM. Comparison of the performance of enzyme immunoassays for hepatitis B and C detection in dried blood spot. *J Immunoassay Immunochem*. 2018;39(2):228–33.
- 7) Flores GL, Cruz HM, Marques VA, Villela-Nogueira CA, Potsch DV, May SB, Brandão-Mello CE, Pires MMA, Pilotto JH, Pollo-Flores P, Esberard EBC, Ivantes C, Lewis-Ximenez LL, Lampe E, Villar LM. Performance of ANTI-HCV testing in dried blood spots and saliva according to HIV status. *J Med Virol*. 2017;89(8):1435–41.
- 8) Lange B, Cohn J, Roberts T, Camp J, Chauffour J, Gummadi N, Ishizaki A, Nagarathnam A, Tuailon E, van de Perre P, Pichler C, Easterbrook P, Denkingier CM. Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses. *BMC Infect Dis*. 2017;17(Suppl 1):700.
- 9) Marques BL, Brandão CU, Silva EF, Marques VA, Villela-Nogueira CA, Do Ó KM, de Paula MT, Lewis-Ximenez LL, Lampe E, Villar LM. Dried blood spot samples: optimization of commercial EIAs for hepatitis C antibody detection and stability under different storage conditions. *J Med Virol*. 2012;84(10):1600–7.
- 10) Villar LM, de Oliveira JC, Cruz HM, Yoshida CF, Lampe E, Lewis-Ximenez LL. Assessment of dried blood spot samples as a simple method for detection of hepatitis B virus markers. *J Med Virol*. 2011;83:1522–9.
- 11) Villar LM, Bezerra CS, Cruz HM, Portilho MM, Flores GL. Applicability of oral fluid and dried blood spot for hepatitis B virus diagnosis. *Can J Gastroenterol Hepatol*. 2019;2019:5672795.
- 12) Altman DG. *Practical statistics for medical research*. London: Chapman and Hall; 1991.
- 13) McCarron B, Fox R, Wilson K, Cameron S, McMenamin J, McGregor G, Pithie A, Golberg D. Hepatitis C antibody detection in dried blood spots. *J Viral Hepatitis*. 1999;6:453–6.
- 14) Tuailon E, Mondain AM, Meroueh F, Ottomani L, Picot MC, Nagot N, Van de Perre P, Ducos J. Dried blood spot for hepatitis C virus serology and molecular testing. *Hepatology*. 2010;51:752–8.